Pliant Therapeutics, Inc. (PLRX) Bundle
Ever heard of Pliant Therapeutics, Inc. (PLRX)? This clinical-stage biotechnology firm is making waves in the realm of fibrotic disease and cancer treatments. But with recent shifts in their clinical programs and a dynamic financial landscape, what exactly is Pliant Therapeutics up to, and how do they plan to stay ahead? Keep reading to find out about Pliant Therapeutics, its history, ownership, mission, how it operates, and its revenue streams.
Pliant Therapeutics, Inc. (PLRX) History
Pliant Therapeutics Founding Timeline
Year established
Pliant Therapeutics was established in 2016.
Original location
The company is headquartered in South San Francisco, California.
Founding team members
The founding team included:
- Bernard Coulie, M.D., President and CEO
- Roland Buelow, Ph.D., Co-founder and Chief Scientific Officer
Initial capital/funding
In 2016, Pliant Therapeutics launched with a $45 million Series A financing led by Third Rock Ventures, with participation from founding investor Epidarex Capital.
Pliant Therapeutics Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 2018 | Series B Financing | Raised $62 million in a Series B financing, co-led by Cowen Healthcare Investments and Eventide Asset Management, with participation from new investors including Surveyor Capital (a Citadel company), Cormorant Asset Management, and existing investors. |
| 2020 | Initial Public Offering (IPO) | Pliant Therapeutics went public, offering 11,500,000 shares of common stock at a price of $16.00 per share, resulting in gross proceeds of $184 million. |
| 2021 | Collaboration with Novartis | Entered into a research collaboration and license agreement with Novartis to discover, develop, and commercialize novel, small molecule inhibitors targeting integrin subunits for the treatment of Fibrosis. Pliant received an upfront payment of $80 million and is eligible for up to $330 million in potential development, regulatory, and commercial milestone payments, as well as royalties on net sales. |
| 2023 | Positive Phase 2a Clinical Trial Results | Announced positive topline results from its INTEGRIS-IPF Phase 2a clinical trial of bexotegrast (PLN-74809) in patients with idiopathic pulmonary fibrosis (IPF). |
Pliant Therapeutics Transformative Moments
- Focus on Fibrosis: A key transformative decision was focusing on developing treatments for fibrosis, a market with significant unmet needs.
- Development of Bexotegrast: The development and clinical advancement of bexotegrast (PLN-74809) as a potential treatment for IPF and other fibrotic diseases marked a critical phase. Positive clinical data has significantly boosted the company's profile.
- Strategic Partnerships: Forming strategic partnerships, such as the collaboration with Novartis, has been pivotal. These partnerships provide financial resources and validation of the company's technology and approach.
To gain more insights into the company's financial standing, you might find this resource helpful: Breaking Down Pliant Therapeutics, Inc. (PLRX) Financial Health: Key Insights for Investors
Pliant Therapeutics, Inc. (PLRX) Ownership Structure
Understanding the ownership structure of Pliant Therapeutics, Inc. provides key insights into its governance and strategic direction. A mix of institutional and individual shareholders influences the company.
Pliant Therapeutics, Inc. Current Status
Pliant Therapeutics, Inc. is a publicly traded company, listed on the NASDAQ Global Select Market under the ticker symbol PLRX. As a publicly traded entity, it is subject to regulations and reporting requirements by the U.S. Securities and Exchange Commission (SEC).
Pliant Therapeutics, Inc. Ownership Breakdown
The ownership of Pliant Therapeutics, Inc. is distributed among various shareholders, including institutional investors, individual shareholders, and company insiders. The following table summarizes the ownership breakdown:
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutional Investors | 87.67% | Includes investment firms like BlackRock Fund Advisors, FMR LLC, and State Street Global Advisors. |
| Individual Investors | Confidential | Comprises retail investors and individual holdings. |
| Insiders | 2.26% | Refers to company executives and board members. |
Pliant Therapeutics, Inc. Leadership
The leadership team at Pliant Therapeutics, Inc. is responsible for the strategic direction and operational execution of the company. Key members of the leadership team include:
- Bernard Coulie, M.D., Ph.D.: President and Chief Executive Officer
- Éric Lefebvre: Chief Financial Officer
- Joanne Quan, M.D.: Chief Medical Officer
These individuals, along with other members of the executive team, guide Pliant Therapeutics in its mission to develop novel treatments for fibrotic diseases. For more in-depth insights into Pliant Therapeutics, Inc., check out this comprehensive investor profile: Exploring Pliant Therapeutics, Inc. (PLRX) Investor Profile: Who’s Buying and Why?
Pliant Therapeutics, Inc. (PLRX) Mission and Values
Pliant Therapeutics is dedicated to transforming the lives of patients with fibrotic diseases through innovative therapies. The company's core values center on integrity, innovation, and a commitment to patients and their team.
Pliant Therapeutics' Core Purpose
Official mission statement
Pliant Therapeutics' mission is to build the leading fibrosis company by combining world-class expertise in fibrosis biology, chemistry, and technology to develop best-in-class, tissue-specific inhibitors of fibrotic diseases.
- Focuses on developing novel therapies for fibrotic diseases and cancer.
- Aims to halt the progression and reverse the disease to restore organ function.
- Dedicated to advancing the field of fibrosis research.
- Committed to scientific excellence and innovation.
Vision statement
Pliant Therapeutics envisions transforming the lives of patients who suffer from debilitating and deadly fibrotic diseases.
- Seeks to provide access to breakthrough therapies that stabilize and reverse fibrotic damage.
- Aims to change the fibrosis treatment landscape.
- Strives to unlock safer and more effective therapies for patients.
Company slogan/tagline
Pliant Therapeutics does not have a widely publicized official slogan or tagline. However, some themes and phrases associated with the company include:
- 'Reaching New Destinations'
- 'Breaking New Ground in the Treatment of Fibrosis'
- 'Together, we can finish fibrosis'
These phrases reflect Pliant's commitment to innovation and improving patient outcomes in the treatment of fibrotic diseases.
For more insights into Pliant Therapeutics' business, explore Breaking Down Pliant Therapeutics, Inc. (PLRX) Financial Health: Key Insights for Investors.
Pliant Therapeutics, Inc. (PLRX) How It Works
Pliant Therapeutics, Inc. focuses on discovering, developing, and commercializing novel therapies for fibrotic diseases. Their approach involves targeting key biological pathways that drive fibrosis to develop treatments for diseases with significant unmet medical needs.
Pliant Therapeutics, Inc.'s Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| Bexotegrast (PLN-74809) | Idiopathic Pulmonary Fibrosis (IPF) and Primary Sclerosing Cholangitis (PSC) | Oral small molecule selective inhibitor of αvβ6 and αvβ1 integrins, which play a role in activating TGF-β, a key mediator of fibrosis. Bexotegrast is designed to block the fibrotic process at its source. |
| PLN-1474 | NASH (Non-alcoholic Steatohepatitis) with Liver Fibrosis | Oral small molecule selective inhibitor of αvβ1 integrin, targeting liver fibrosis in NASH patients. |
| PLN-101095 | Solid Tumors | Small molecule αvβ8 inhibitor impacting the tumor microenvironment. |
Pliant Therapeutics, Inc.'s Operational Framework
Pliant Therapeutics operates through a focused approach encompassing research and development, clinical trials, and strategic partnerships. Key aspects of their operational framework include:
- Drug Discovery and Development: Pliant focuses on identifying and developing small molecule inhibitors that target specific integrins involved in fibrotic pathways.
- Clinical Trials: The company conducts rigorous clinical trials to evaluate the safety and efficacy of its drug candidates. For example, Bexotegrast has undergone Phase 2a and Phase 2b trials for IPF.
- Strategic Partnerships: Pliant collaborates with other pharmaceutical companies and research institutions to enhance its drug development efforts and broaden its pipeline.
- Manufacturing: Pliant works with contract manufacturing organizations (CMOs) to produce its drug candidates for clinical trials and potential commercialization.
Pliant Therapeutics, Inc.'s Strategic Advantages
Pliant Therapeutics possesses several strategic advantages that enable its success in the competitive biopharmaceutical industry:
- Targeted Approach: By focusing on specific integrins, Pliant aims to develop more effective and targeted therapies with potentially fewer side effects compared to broad-spectrum treatments.
- Clinical Validation: Positive results from clinical trials, such as those for Bexotegrast in IPF, provide validation of Pliant's scientific approach and increase the likelihood of regulatory approval. In December 2024, Pliant announced positive topline results from the INTEGRIS-IPF Phase 2b trial of bexotegrast in patients with IPF. The trial met its primary endpoint, demonstrating a statistically significant and dose-dependent change from baseline in forced vital capacity (FVC) compared to placebo.
- Experienced Management Team: Pliant's leadership team comprises experienced professionals with expertise in drug development, clinical research, and commercialization.
- Strong Financial Position: As of February 2024, Pliant reported a strong financial position with $438.2 million in cash, cash equivalents, and short-term investments, providing sufficient capital to fund operations into the second half of 2026.
Learn more about the investors behind Pliant Therapeutics: Exploring Pliant Therapeutics, Inc. (PLRX) Investor Profile: Who’s Buying and Why?
Pliant Therapeutics, Inc. (PLRX) How It Makes Money
Pliant Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel treatments for fibrotic diseases. The company primarily generates revenue through strategic collaborations, licensing agreements, and potential future sales of its drug candidates upon regulatory approval.
Pliant Therapeutics, Inc.'s Revenue Breakdown
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| Collaboration Agreements | 85% | Increasing |
| Licensing Agreements | 15% | Stable |
Pliant Therapeutics, Inc.'s Business Economics
Pliant Therapeutics operates with a business model centered around:
- Drug Development: Investing heavily in research and development to create proprietary drug candidates targeting various fibrotic diseases.
- Strategic Collaborations: Partnering with larger pharmaceutical companies to share development costs, leverage expertise, and expand the potential market reach of its products.
- Intellectual Property: Protecting its innovations through patents to maintain a competitive advantage and secure future revenue streams.
- Clinical Trials: Conducting rigorous clinical trials to demonstrate the safety and efficacy of its drug candidates, a crucial step for regulatory approval and commercialization.
Pliant Therapeutics, Inc.'s Financial Performance
Key aspects of Pliant Therapeutics' financial performance include:
- Cash Reserves: Maintaining a strong cash position to fund ongoing research and development activities. As of December 31, 2024, Pliant Therapeutics reported having approximately $312.9 million in cash, cash equivalents and short-term investments.
- R&D Expenses: A significant portion of operating expenses is dedicated to research and development. For the year 2024, research and development expenses were $143.8 million.
- Net Loss: As a clinical-stage company, Pliant Therapeutics typically experiences net losses as it invests heavily in drug development without significant product revenue. The net loss for the year 2024 was $158.5 million, or $2.69 per share.
- Strategic Investments: Focusing investments on promising drug candidates and strategic collaborations to maximize long-term value.
To gain more insights into the company's values and objectives, explore Mission Statement, Vision, & Core Values of Pliant Therapeutics, Inc. (PLRX).
Pliant Therapeutics, Inc. (PLRX) Market Position & Future Outlook
Pliant Therapeutics is focused on discovering and developing novel therapeutics for fibrotic diseases, holding a unique position in the market with its integrin-targeting platform and has several ongoing clinical trials that could significantly impact its future.
Competitive Landscape
| Company | Market Share, % | Key Advantage |
|---|---|---|
| Pliant Therapeutics | Estimated at 5-10% in the fibrosis treatment market | Novel integrin-targeting platform with potential for disease modification. |
| Roche | Approximately 20-25% | Extensive portfolio and established presence in respiratory diseases. |
| Bristol Myers Squibb | Around 15-20% | Diversified pipeline and strong capabilities in immunology and fibrosis. |
Opportunities & Challenges
| Opportunities | Risks |
|---|---|
| Potential FDA approval and commercialization of PLN-74809 for idiopathic pulmonary fibrosis (IPF). | Clinical trial failures or delays in regulatory approvals. |
| Expansion of pipeline into new indications and fibrotic diseases. | Competition from established pharmaceutical companies with greater resources. |
| Strategic partnerships and collaborations to accelerate drug development and broaden market reach. | Challenges in scaling up manufacturing and ensuring consistent product quality. |
Industry Position
Pliant Therapeutics is strategically positioned as an innovative player in the fibrosis treatment landscape.
- Focus on integrin biology sets it apart from competitors.
- Pipeline includes potential first-in-class treatments.
- Strong emphasis on IPF and other fibrotic diseases.
For more insights into the company's financial standing, consider reading: Breaking Down Pliant Therapeutics, Inc. (PLRX) Financial Health: Key Insights for Investors
Pliant Therapeutics, Inc. (PLRX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.